Madrigal Pharmaceuticals, Inc. (MDGL)
MDGL Stock Price Chart
Explore Madrigal Pharmaceuticals, Inc. interactive price chart. Choose custom timeframes to analyze MDGL price movements and trends.
MDGL Company Profile
Discover essential business fundamentals and corporate details for Madrigal Pharmaceuticals, Inc. (MDGL) to support your stock research and investment decisions.
Sector
Healthcare
Industry
Biotechnology
IPO Date
6 Feb 2007
Employees
528.00
Website
https://www.madrigalpharma.comCEO
William J. Sibold
Description
Madrigal Pharmaceuticals, Inc. is a biopharmaceutical company in the clinical development phase, concentrating its efforts on discovering and commercializing innovative treatments for cardiovascular, metabolic, and liver disorders. Its most advanced drug candidate, resmetirom, functions as a liver-targeted selective thyroid hormone receptor-ß agonist, currently undergoing late-stage (Phase III) clinical trials for managing non-alcoholic steatohepatitis (NASH). The company's pipeline also features MGL-3745, which serves as a secondary or backup compound to resmetirom. Madrigal holds a collaborative agreement with Hoffmann-La Roche, encompassing research, development, and commercialization activities. The company's operations are based out of West Conshohocken, Pennsylvania.
MDGL Financial Timeline
Browse a chronological timeline of Madrigal Pharmaceuticals, Inc. corporate events including earnings releases, dividend announcements, and stock splits.
Upcoming earnings on 30 Jul 2026
EPS estimate is -$2.66, while revenue estimate is $350.85m.
Earnings released on 6 May 2026
EPS came in at -$3.25 surpassing the estimated -$3.61 by +9.97%, while revenue for the quarter reached $311.34m , beating expectations by +3.42%.
Earnings released on 19 Feb 2026
EPS came in at -$2.57 falling short of the estimated $0.04 by -6.53k%, while revenue for the quarter reached $321.10m , beating expectations by +2.75%.
Earnings released on 4 Nov 2025
EPS came in at -$5.08 falling short of the estimated -$2.04 by -149.38%, while revenue for the quarter reached $287.27m , beating expectations by +17.27%.
Earnings released on 5 Aug 2025
EPS came in at -$1.90 surpassing the estimated -$3.48 by +45.40%, while revenue for the quarter reached $212.80m , missing expectations by -12.59%.
Earnings released on 1 May 2025
EPS came in at -$3.32 surpassing the estimated -$3.62 by +8.29%, while revenue for the quarter reached $137.25m , missing expectations by -13.64%.
Earnings released on 26 Feb 2025
EPS came in at -$2.71 surpassing the estimated -$4.32 by +37.27%, while revenue for the quarter reached $103.32m , beating expectations by +5.64%.
Earnings released on 31 Oct 2024
EPS came in at -$4.92 surpassing the estimated -$6.94 by +29.11%, while revenue for the quarter reached $62.18m , missing expectations by -32.80%.
Earnings released on 7 Aug 2024
EPS came in at -$7.10 surpassing the estimated -$7.55 by +5.96%, while revenue for the quarter reached $14.64m , beating expectations by +275.33%.
Earnings released on 7 May 2024
EPS came in at -$7.38 falling short of the estimated -$6.06 by -21.78%.
Earnings released on 28 Feb 2024
EPS came in at -$5.68 falling short of the estimated -$5.32 by -6.77%, while revenue for the quarter reached $770.00k .
Earnings released on 6 Nov 2023
EPS came in at -$5.34 falling short of the estimated -$4.78 by -11.72%.
Earnings released on 8 Aug 2023
EPS came in at -$4.69 falling short of the estimated -$4.47 by -4.92%.
Earnings released on 9 May 2023
EPS came in at -$4.23 surpassing the estimated -$4.98 by +15.06%.
Earnings released on 23 Feb 2023
EPS came in at -$4.98 falling short of the estimated -$4.41 by -12.93%.
Earnings released on 3 Nov 2022
EPS came in at -$4.75 falling short of the estimated -$4.05 by -17.28%.
Earnings released on 4 Aug 2022
EPS came in at -$4.14 falling short of the estimated -$3.76 by -10.11%.
Earnings released on 9 May 2022
EPS came in at -$3.36 surpassing the estimated -$3.75 by +10.40%.
Earnings released on 24 Feb 2022
EPS came in at -$3.78 surpassing the estimated -$3.92 by +3.57%.
Earnings released on 4 Nov 2021
EPS came in at -$3.79 surpassing the estimated -$3.89 by +2.57%.
Earnings released on 5 Aug 2021
EPS came in at -$3.72 falling short of the estimated -$3.55 by -4.79%.
MDGL Stock Performance
Access detailed MDGL performance analysis with candlestick charts, real‑time intraday data and historical financial metrics for comprehensive insights.
Explore Related Stocks
Compare companies within the same sector by viewing performance, key financials, and market trends. Select a symbol to access the full profile.
